$0.21
0.00 (-0.72%)
Open$0.21
Previous Close$0.21
Day High$0.22
Day Low$0.21
52W High$20.77
52W Low$11.50
Volume—
Avg Volume141.8K
Market Cap2.23M
P/E Ratio52.28
EPS$0.38
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+11,986.5% upside
Current
$0.21
$0.21
Target
$25.14
$25.14
$18.28
$25.14 avg
$30.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 479.4K | 427.8K | 407.2K |
| Net Income | 44.8K | 33.9K | 31.0K |
| Profit Margin | 9.3% | 7.9% | 7.6% |
| EBITDA | 75.7K | 68.2K | 60.9K |
| Free Cash Flow | 30.2K | 23.2K | 18.1K |
| Rev Growth | +9.0% | +6.7% | +7.5% |
| Debt/Equity | 0.32 | 0.27 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |